In Section A, contributors will obtain unique doses and schedules of oral ABBV-744 pill to recognize Harmless dosing regimen. Added contributors might be enrolled in the recognized monotherapy dosign routine. In Section B, contributors will acquire oral ruxolitinib and ABBV-744 will likely be supplied as "add-on" therapy. In Phase C, https://edmundk665whr8.madmouseblog.com/profile